This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brantley, M. A. Articles by Harbour, J. W. Search for Related Content PubMed PubMed Citation Articles by Brantley, M. A., Jr. Articles by Harbour, J. W.

(American Journal of Pathology. 2000;157:1795-1801.)
© 2000 American Society for Investigative Pathology

Short Communications

Deregulation of the Rb and p53 Pathways in Uveal Melanoma

From the Department of Ophthalmology and Visual Sciences and Division of Molecular Oncology, Washington University, St. Louis, Missouri

Uveal melanoma is the most common primary eye cancer, yet its molecular pathogenesis is poorly understood. In this study, we investigated the immunohistochemical expression of proteins in the Rb and p53 tumor suppressor pathways in 33 uveal melanomas from enucleated eyes. Strong nuclear staining for Rb was present in most tumors. However, a few cases displayed weak nuclear staining and strong cytoplasmic staining (possibly indicating Rb mutation), and this aberrant staining correlated strongly with failed radiotherapy or thermotherapy before enucleation. Staining for cyclin D1 was positive in most tumors and was associated with advanced age and larger tumor size, which are both poor prognostic factors. Generally, immunostaining for p53 was weak (suggesting a lack of p53 mutations), although p53 positivity correlated strongly with staining for phosphorylated Rb, supporting the notion that inappropriate phosphorylation of Rb can induce p53. Strong immunostaining for MDM2, which can functionally block p53 activity, was observed in most tumors and correlated significantly with female sex. Strong cytoplasmic staining was observed for Bcl2, which can inhibit both p53-dependent and -independent apoptosis. We conclude that Rb and p53 are mutated infrequently in uveal melanoma, but their respective pathways may be functionally inactivated.

This article has been cited by other articles:

				G. Lefevre, N. Babchia, A. Calipel, F. Mouriaux, A.-M. Faussat, S. Mrzyk, and F. Mascarelli Activation of the FGF2/FGFR1 Autocrine Loop for Cell Proliferation and Survival in Uveal Melanoma Cells Invest. Ophthalmol. Vis. Sci., March 1, 2009; 50(3): 1047 - 1057. [Abstract] [Full Text] [PDF]

				M. D. Onken, L. A. Worley, M. D. Long, S. Duan, M. L. Council, A. M. Bowcock, and J. W. Harbour Oncogenic Mutations in GNAQ Occur Early in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., December 1, 2008; 49(12): 5230 - 5234. [Abstract] [Full Text] [PDF]

				A. Sekulic, P. Haluska Jr, A. J. Miller, J. G. De Lamo, S. Ejadi, J. S. Pulido, D. R. Salomao, E. C. Thorland, R. G. Vile, D. L. Swanson, et al. Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape Mayo Clin. Proc., July 1, 2008; 83(7): 825 - 846. [Abstract] [Full Text] [PDF]

				W. van Gils, H. W. Mensink, E. Kilic, J. Vaarwater, M. M. Verbiest, D. Paridaens, G. P. Luyten, A. de Klein, and H. T. Bruggenwirth Expression of APITD1 Is Not Related to Copy Number Changes of Chromosomal Region 1p36 or the Prognosis of Uveal Melanoma Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 4919 - 4923. [Abstract] [Full Text] [PDF]

				J. W. Harbour Eye Cancer: Unique Insights into Oncogenesis The Cogan Lecture Invest. Ophthalmol. Vis. Sci., May 1, 2006; 47(5): 1737 - 1745. [Full Text] [PDF]

				M. R. Hussein, A. K. Haemel, D. M. Albert, and G. S. Wood Microsatellite Instability and Alterations of Mismatch Repair Protein Expression in Choroidal Melanomas Arch Ophthalmol, December 1, 2005; 123(12): 1705 - 1711. [Abstract] [Full Text] [PDF]

				J. P. Ehlers, L. Worley, M. D. Onken, and J. W. Harbour DDEF1 Is Located in an Amplified Region of Chromosome 8q and Is Overexpressed in Uveal Melanoma Clin. Cancer Res., May 15, 2005; 11(10): 3609 - 3613. [Abstract] [Full Text] [PDF]

				Y. Sun, B. N. Tran, L. A. Worley, R. B. Delston, and J. W. Harbour Functional Analysis of the p53 Pathway in Response to Ionizing Radiation in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., May 1, 2005; 46(5): 1561 - 1564. [Abstract] [Full Text] [PDF]

				M R Hussein Analysis of Bcl-2 protein expression in choroidal melanomas J. Clin. Pathol., May 1, 2005; 58(5): 486 - 489. [Abstract] [Full Text] [PDF]

				J. P. Ehlers and J. W. Harbour NBS1 Expression as a Prognostic Marker in Uveal Melanoma Clin. Cancer Res., March 1, 2005; 11(5): 1849 - 1853. [Abstract] [Full Text] [PDF]

				M. D. Onken, L. A. Worley, J. P. Ehlers, and J. W. Harbour Gene Expression Profiling in Uveal Melanoma Reveals Two Molecular Classes and Predicts Metastatic Death Cancer Res., October 15, 2004; 64(20): 7205 - 7209. [Abstract] [Full Text] [PDF]

				A. Biroccio, S. Amodei, A. Antonelli, B. Benassi, and G. Zupi Inhibition of c-Myc Oncoprotein Limits the Growth of Human Melanoma Cells by Inducing Cellular Crisis J. Biol. Chem., September 12, 2003; 278(37): 35693 - 35701. [Abstract] [Full Text] [PDF]

				W. J. Foster, C. E. Fuller, A. Perry, and J. W. Harbour Status of the NF1 Tumor Suppressor Locus in Uveal Melanoma Arch Ophthalmol, September 1, 2003; 121(9): 1311 - 1315. [Abstract] [Full Text] [PDF]

				S. H. Smith, M. H. Goldschmidt, and P. M. McManus A Comparative Review of Melanocytic Neoplasms Vet. Pathol., November 1, 2002; 39(6): 651 - 678. [Abstract] [Full Text] [PDF]

				J. W. Harbour, L. Worley, D. Ma, and M. Cohen Transducible Peptide Therapy for Uveal Melanoma and Retinoblastoma Arch Ophthalmol, October 1, 2002; 120(10): 1341 - 1346. [Abstract] [Full Text] [PDF]